PMID-35368070 – Long-term Safety of Growth Hormone in 15,809 Adults
Johannsson G et al. "Safety of Growth Hormone Replacement in Adults With Growth Hormone Deficiency: Results From a Large Observational Study," Journal of Clinical Endocrinology & Metabolism, 2022;107(8):e3198-e3209. doi:10.1210/clinem/dgac199
Quick Reference
| Property | Value |
|---|---|
| PMID | 35368070 |
| DOI | 10.1210/clinem/dgac199 |
| Year | 2022 |
| Journal | Journal of Clinical Endocrinology & Metabolism |
| Study Type | Observational (prospective registry) |
| Evidence Level | III |
| Sample | n=15,809 GH-treated adults |
| Peptide(s) Studied | GH-axis peptides (exogenous GH therapy as proxy) |
Key Findings
- REASSURING: Cancer standardized incidence ratio (SIR) of 0.92 in GH-treated adults — comparable to the general population
- No increased risk of de novo malignancy with long-term GH replacement therapy
- No increased recurrence risk in patients with history of prior malignancy
- Results consistent across age groups, sex, and GH deficiency etiology
- Long follow-up duration strengthens the safety signal
- This is the largest safety dataset for GH replacement therapy in adults to date
Study Design
Prospective observational registry study (KIMS — Pfizer International Metabolic Database) tracking 15,809 adults with GH deficiency receiving GH replacement therapy. Cancer incidence compared to age- and sex-matched general population rates using standardized incidence ratios. Extended follow-up period of up to 20 years for some patients.
Limitations
- Observational design; no randomized control group
- Registry data may be subject to ascertainment bias (closer monitoring in GH-treated patients)
- GH doses used in replacement therapy may differ from doses achieved by GH-secretagogue peptides
- Industry-sponsored registry (Pfizer)
- Healthy user effect possible — patients deemed too high-risk may not have been enrolled
Clinical Relevance
This is the key reassurance study for GH-axis peptide prescribing. With 15,809 patients and up to 20 years of follow-up, the SIR of 0.92 provides strong evidence that physiological GH replacement does not increase cancer risk. This directly counters the alarming signal from Deodati 2014 (PMID-24818783) by using a much larger, better-controlled cohort. For practitioners using CJC-1295, Ipamorelin, Tesamorelin, or other GH-axis peptides, this study supports safety when IGF-1 is monitored within physiological ranges.
Related
#research #observational #evidence-level-III #cancer